ESC Premium Access

Improving management of heart failure with reduced ejection fraction with sglt2i's using the latest clinical data: an online education intervention

Congress Session

About the speaker

Doctor Anne Sendaydiego

Louisville (United States of America)
0 follower

46 more presentations in this session

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Speaker: Doctor A. Sharma (Montreal, CA)

Thumbnail

SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis

Speaker: Doctor V. Razuk (New York, US)

Thumbnail

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

Speaker: Doctor G. Gager (Vienna, AT)

Thumbnail

Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin

Speaker: Doctor J. Kolwelter (Erlangen, DE)

Thumbnail

Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial

Speaker: Doctor M. Senni (Bergamo, IT)

Thumbnail

Access the full session

Congress committee e-posters choice in heart failure

Speakers: Doctor A. Sendaydiego, Doctor A. Sharma, Doctor V. Razuk, Doctor G. Gager, Doctor J. Kolwelter...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

Cardiovascular outcome in patients treated with SGLT2 inhibitors for heart failure: a meta-analysis

27 August 2021

ESC Premium Access

Empagliflozin reduces TNFa-induced reactive oxygen species through inhibition of the human endothelial Na+/H+ exchanger 1

27 August 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by

logo Novo Nordisk